Patents
Methods of Investigating, Diagnosing, and Treating Amyloidosis
The present invention provides a therapeutic method for removing amyloid fibrils from a patient. The present invention also provides a transgenic animal that develops systemic AA amyloidosis within three weeks for use as a tool to investigate AA amyloidosis and to evaluate agents that may be potentially useful in preventing and treating amyloid-related disorders. Further, the present invention provides diagnostic assays for monitoring immunoglobulin light chain fibrillogenesis in real-time and for identification of the chemical nature of the protein in amyloid deposits which enables the determination of the type of amyloidosis for therapeutic and prognostic purposes.
Inventors: Alan Solomon, MD; Jonathan Wall, PhD; Rudi Hrncic; Maria Schell.
Flow Cytometric Characterization of Amyloid Fibrils
A method of detecting amyloid fibrils in biological samples utilizing flow cytometry is described. It has been found that the measurement of fluorescence from amyloidophilic dyes, such as thioflavin T and Congo red, as well as side scatter and forward scatter measurements are particularly useful in detecting the presence of amyloid fibrils. Flow cytometric detection of amyloid fibrils in subjects such as humans and livestock can be employed for diagnosis, assessment of therapeutic efficacy, research, and monitoring of livestock for the presence of infectious amyloidosis.
Inventor: Jonathan Wall, PhD
Provisional Patents:
Peptides that Specifically Target Amyloid Deposits
The present invention provides a novel method of detecting amyloids in a subject. The present invention provides peptides that bind selectively to amyloids and are useful for detecting amyloids and diagnosing and/or monitoring the progression of amyloid mediated conditions.
Inventors: Jonathan Wall, PhD
Stephen Kennell, PhD
Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
The present invention provides a method of purifying cross-linked oligomers. The purified cross-linked oligomers are useful as immunogen for generating and isolating cross-linked oligomer reactive antibodies. The cross-linked oligomer reactive antibodies are useful for detecting amyloid deposition and for diagnosing and treating diseases and conditions associated with amyloid deposition.
Inventors:
O'nuallain, Brian
Solomon, Alan
Wall, Jonathan S.
Acero, Luis
Williams, Angela
Methods for diagnosis or treatment of amyloidosis by targeting hyper-sulfated proteoglycans present in amyloid
Amyloid in an individual may be targeted by systemically administering to an individual a ligand that binds to a hyper-sulfated proteoglycan and permitting the ligand to bind to hyper-sulfated proteoglycans associated with amyloid within the body of the individual.
Inventors:
Wall, Jonathan
Kennel, Stephen
Van Kuppevelt, Toin
Smits, Nicole
Treatment and prophylaxis of amyloidosis
Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
Inventors:
Schenk, Dale B.
Seubert, Peter A.
Wall, Jonathan
Saldanha, Jose W.
Methods for amyloid removal using anti-amyloid antibodies
Methods and related immunoglobulin peptides and fragments thereof are disclosed that enhance the cell-mediated immune response of a patient to deposits of amyloid fibrils. These methods exploit the opsonizing effect of antibodies directed toward amyloid material or its component parts.
Inventors:
Solomon, Alan
Hrncic, Rudi
Wall, Jonathan
Diagnostic and Therapeutic Potential of Immune Globulin Intravenous (IGIV) Products
The present invention provides IGIV and IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The present invention also provides methods for obtaining IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The IGIV recognizes amyloid fibrils and partially denatured amyloidogenic precursor polypeptides. They are useful for treating diseases and conditions associated with amyloid deposition. The IGIV of the present invention also are useful for diagnosing and detecting amyloid deposition.
Inventors:
O'nuallain, Brian
Hrncic, Rudi
Wall, Jonathan S.
Solomon, Alan
The University of Tennessee Graduate School of Medicine
Preclinical and Diagnostic Molecular Imaging Laboratory
1924 Alcoa Highway
Knoxville, TN
37920-6999
Phone: 865 305 8497